Dose escalation of chart in non-small cell lung cancer: Is three-dimensional conformal radiation therapy really necessary?

被引:25
|
作者
McGibney, C
Holmberg, O
McClean, B
Williams, C
McCrea, P
Sutton, P
Armstrong, J
机构
[1] St Lukes Hosp, Dept Radiat Oncol, Dublin 6, Ireland
[2] St Lukes Hosp, Dept Phys, Dublin 6, Ireland
[3] St Lukes Hosp, Dept Radiol, Dublin 6, Ireland
[4] St Lukes Hosp, Dept Therapeut Radiog, Dublin 6, Ireland
关键词
three-dimensional; conformal radiation therapy; lung cancer; CHART; elective nodal irradiation; hyperfractionation; acceleration;
D O I
10.1016/S0360-3016(99)00095-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate, preclinically, the potential for dose escalation of continuous, hyperfractionated, accelerated radiation therapy (CHART) for non small-cell lung cancer (NSCLC), we examined the strategy of omission of elective nodal irradiation with and without the application of three-dimensional conformal radiation technology (3DCRT). Methods and Materials: 2D, conventional therapy plans were designed according to the specifications of CHART for 18 patients with NSCLC (Stages Ib, IIb, IIIa, and IIIb). Further plans were generated with the omission of elective nodal irradiation (ENI) from the treatment portals (2D minus ENI plans [2D-ENI plans]). Both sets were inserted in the patient's planning computed tomographies (CTs). These reconstructed plans were then compared to alternative, three dimensional treatment plans which had been generated de novo, with the omission of ENI: 3D minus elective nodal irradiation (3D-ENI plans). Dose delivery to the planning target volumes (PTVs) and to the organs at risk were compared between the 3 sets of corresponding plans. The potential for dose escalation of each patient's 2D-ENI and 3D-ENI plan beyond 54 Gy, standard to CHART, was also determined. Results: PTV coverage was suboptimal in the 2D CHART and the 2D-ENI plans. Only in the 3D-ENI plans did 100% of the PTV get greater than or equal to 95% of the dose-prescribed (i.e., 51.5 Gy [51.3-52.2]). Using 3D-ENI plans significantly reduced the dose received by the spinal cord, the mean and median doses to the esophagus and the heart. It did not significantly reduce the lung dose when compared to 2D-ENI plans. Escalation of the dose (minimum greater than or equal to 1 Gy) with optimal PTV coverage was possible in 55.5% of patients using 3D-ENI, but was possible only in 16.6% when using the 2D-ENI planning strategy. Conclusions: 3DCRT is fundamental to achieving optimal PTV coverage in NSCLC. A policy of omission of elective nodal irradiation alone (and using 2D technology) will not achieve optimal PTV coverage or dose escalation. 3DCRT with omission of ENI can achieve true escalation of CHART in 55.5% of tumors, depending on their site and N-stage. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:339 / 350
页数:12
相关论文
共 50 条
  • [41] A Phase I Dose Escalation Study using Three-dimensional Conformal Radiotherapy with Concurrent Cisplatin and S-1 in Patients with Stage III Non-small Cell Lung Cancer
    Kozuka, T.
    Harada, H.
    Nishio, M.
    Murakami, H.
    Ohyanagi, F.
    Ishikura, S.
    Horiike, A.
    Morota, M.
    Nishimura, T.
    Yamamoto, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S473 - S474
  • [42] Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer
    Yendamuri, Sai
    Komaki, Ritsuko R.
    Correa, Arlene M.
    Allen, Pamela
    Wynn, Bob
    Blackmon, Shanda
    Hofstetter, Wayne L.
    Rice, David C.
    Roth, Jack A.
    Swisher, Stephen G.
    Vaporciyan, Ara A.
    Walsh, Garrett L.
    Mehran, Reza J.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (11) : 1022 - 1028
  • [43] Radiation dose escalation in patients with non-small cell lung cancer facilitated by the use of the cytoprotectant amifostine
    Nichols, R
    Neuenfeldt, L
    England, G
    Mahmood, S
    Nanfro, J
    Malamud, F
    Sweetser, M
    Varner, J
    LUNG CANCER, 2005, 49 : S312 - S312
  • [44] Lung and Heart Dose Variability During Radiation Therapy of Non-Small Cell Lung Cancer
    Jan, Nuzhat
    Guy, Christopher
    Reshko, Leonid B.
    Hugo, Geoffrey D.
    Weiss, Elisabeth
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (03): : 683 - 690
  • [45] Three-dimensional conformal involved-field radiotherapy for stage III non-small cell lung cancer.
    Yuan, S., Sr.
    Yu, J.
    Sun, X., Sr.
    Li, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 375S - 375S
  • [46] Dose escalation in radiation therapy of non-small cell lung cancer. Can we use the traditional gamma units?
    Kcharchenco, V
    Panshin, G.
    Sotnikov, V
    Ilin, M.
    LUNG CANCER, 2007, 55 : S6 - S6
  • [47] Dose Escalation, Not "New Biology," Can Account for the Efficacy of Stereotactic Body Radiation Therapy With Non-Small Cell Lung Cancer
    Brown, J. Martin
    Brenner, David J.
    Carlson, David J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (05): : 1159 - 1160
  • [48] Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer
    Sim, S
    Rosenzweig, KE
    Schindelheim, R
    Ng, KK
    Leibel, SA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03): : 660 - 665
  • [49] Variability of Lung Volumes and Lung Dose During Radiation Therapy of Non-Small Cell Lung Cancer
    Jan, N.
    Reshko, L. B.
    Guy, C.
    Sleeman, W.
    Rosu, M.
    Hugo, G. D.
    Weiss, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E456 - E456
  • [50] Predictors of High-grade Esophagitis After Definitive Three-dimensional Conformal Therapy, Intensity-modulated Radiation Therapy, or Proton Beam Therapy for Non-small cell Lung Cancer
    Gomez, Daniel R.
    Tucker, Susan L.
    Martel, Mary K.
    Mohan, Radhe
    Balter, Peter A.
    Lopez Guerra, Jose Luis
    Liu, Hongmei
    Komaki, Ritsuko
    Cox, James D.
    Liao, Zhongxing
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (04): : 1010 - 1016